
The resurgence of neuroscience
Bram Goorden, CEO, IXICO, looks at why precision medicine is the next frontier for neuroscience. For much of the early 2000s, neuroscience was one of the pharmaceutical industry’s most challenging therapeutic areas. Clinical failures accumulated and investors increasingly favoured oncology, where biomarker-driven drug development… Read More















